Key Takeaways
- • Redalpine closed its eighth fund, Redalpine Capital VIII, at a $250 million hard cap, and the fund was oversubscribed, according to the firm.
- • The fund is 25% larger than its predecessor, Redalpine Capital VII, which closed at $200 million in 2024, and closed in less than 12 months from first to final close.
- • The closing contrasts with a weak European and German-speaking VC fundraising market, where PitchBook data show only 21 funds closing for €2 billion in the first nine months of 2025.
- • Around one-third of the new fund's capital came from institutions Redalpine had not previously worked with, including several pension funds and insurance companies.
- • Redalpine plans to back around 20 companies in the new fund, typically writing checks of $1 million to $15 million, and reserves up to 50% of the fund for follow-on rounds in existing portfolio companies.
Summary
Swiss venture capital investor Redalpine has closed its eighth fund, Redalpine Capital VIII, at $250 million. According to the firm, the fund reached its hard cap and was oversubscribed, with less than 12 months between the first and final closings. The result stands out in a difficult fundraising environment for European venture capital. The predecessor, Redalpine Capital VII, closed at $200 million in 2024, making the new vehicle 25% larger.
The closing runs against broader market data. According to PitchBook, 83 venture capital funds closed in German-speaking countries in 2022, raising a combined €6.2 billion. In the first nine months of 2025, only 21 funds closed, raising a total of €2 billion, and the median time from launch to final close most recently stood at 26 months. Redalpine's quick close suggests that institutional and private investors still commit capital to established European managers with a clear strategy.
Founded in Zurich in 2006, Redalpine has since moved its headquarters to Zug and maintains offices in Berlin and London. It focuses on European early-stage companies, primarily leading seed and Series A rounds, and holds investments in more than 100 companies. The new fund is expected to finance around 20 companies. Roughly half of the investment team has academic backgrounds in the natural sciences or technical disciplines. Recent investments from the eighth fund include Zurich-based Enact Intelligence, Berlin-based telli, Munich-based microagi, and Paris-based Arlequin AI. Redalpine also cited London-based Helical, which operates an AI lab.
The firm points to a track record of exits from its life sciences portfolio. Araris Biotech was acquired by Japanese pharmaceutical company Taiho in a deal with a potential total value of up to $1.14 billion including milestones. Ipsen acquired Swiss biotech Memo Therapeutics in a transaction with potential total value above €700 million. Other exits include Lunaphore, sold to Bio-Techne, and AI security company Lakera, sold to Check Point. Redalpine also led the seed round for Munich-based Proxima Fusion, which was valued at €2.4 billion in July.
In an interview with transkript, Redalpine attributed its fundraising success to delivered returns, saying investors are concentrating capital among managers with a track record of distributions. Rafael Hubatschek, Partner and Head of Investor Relations, said that "Europe's confidence is back" and that institutional investors are now investing in European technology "with full conviction." Redalpine said up to 50% of the fund may be reserved for follow-on rounds, and that it will bring co-investors into larger later rounds when warranted.
The closing runs against broader market data. According to PitchBook, 83 venture capital funds closed in German-speaking countries in 2022, raising a combined €6.2 billion. In the first nine months of 2025, only 21 funds closed, raising a total of €2 billion, and the median time from launch to final close most recently stood at 26 months. Redalpine's quick close suggests that institutional and private investors still commit capital to established European managers with a clear strategy.
Founded in Zurich in 2006, Redalpine has since moved its headquarters to Zug and maintains offices in Berlin and London. It focuses on European early-stage companies, primarily leading seed and Series A rounds, and holds investments in more than 100 companies. The new fund is expected to finance around 20 companies. Roughly half of the investment team has academic backgrounds in the natural sciences or technical disciplines. Recent investments from the eighth fund include Zurich-based Enact Intelligence, Berlin-based telli, Munich-based microagi, and Paris-based Arlequin AI. Redalpine also cited London-based Helical, which operates an AI lab.
The firm points to a track record of exits from its life sciences portfolio. Araris Biotech was acquired by Japanese pharmaceutical company Taiho in a deal with a potential total value of up to $1.14 billion including milestones. Ipsen acquired Swiss biotech Memo Therapeutics in a transaction with potential total value above €700 million. Other exits include Lunaphore, sold to Bio-Techne, and AI security company Lakera, sold to Check Point. Redalpine also led the seed round for Munich-based Proxima Fusion, which was valued at €2.4 billion in July.
In an interview with transkript, Redalpine attributed its fundraising success to delivered returns, saying investors are concentrating capital among managers with a track record of distributions. Rafael Hubatschek, Partner and Head of Investor Relations, said that "Europe's confidence is back" and that institutional investors are now investing in European technology "with full conviction." Redalpine said up to 50% of the fund may be reserved for follow-on rounds, and that it will bring co-investors into larger later rounds when warranted.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.